ANTARES PHARMA, INC. Inactive Instrument
Antares Pharma, Inc. Share Price
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Steven N. Knapp
LAW | General Counsel | - | - |
| Corporate Officer/Principal | 76 | 01/94/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Helen Torley
BRD | Director/Board Member | 61 | 24/22/24 |
Thomas Bergmann
BRD | Director/Board Member | - | - |
Nicole LaBrosse
BRD | Director/Board Member | 41 | 24/22/24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 509 M€ | -.--% |
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
